StockNews.AI
LUNG
StockNews.AI
37 days

Pulmonx to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

1. Pulmonx will release Q4 and full year 2024 results on Feb 19, 2025. 2. Management will host a conference call at 1:30 PM PT to discuss results. 3. Pulmonx is a leader in minimally invasive treatments for COPD. 4. The Zephyr Valve is a standard care option for severe emphysema. 5. The FDA approved the Zephyr Valve as a breakthrough device.

Earnings
+4.55%Current Return
VS
+0.34%S&P 500
$6.1502/05 04:07 PM EDTEvent Start
$6.4302/06 10:28 PM EDTLatest Updated
3 mins saved
Full Article

FAQ

Why Bullish?

Upcoming earnings report could demonstrate strong revenue growth. Past earnings reports have positively influenced LUNG's stock.

How important is it?

Earnings reports typically influence stock prices significantly, and Pulmonx's strong product position may drive investor interest.

Why Short Term?

Earnings release effects will be immediate. Historical trends show earnings announcements impact stock prices significantly in the short term.

Related Companies

COPDZSANAVGR
February 05, 2025 16:05 ET  | Source: Pulmonx Corporation REDWOOD CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2024 after the close of trading on Wednesday, February 19, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraX™ Platform, and StratX® Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com. ContactBrian JohnstonGilmartin Groupinvestors@pulmonx.com

Related News